100 related articles for article (PubMed ID: 27141654)
1. [INSULIN GLARGINE 300 U/mL (TOUJEO®)].
Scheen AJ
Rev Med Liege; 2016 Feb; 71(2):101-7. PubMed ID: 27141654
[TBL] [Abstract][Full Text] [Related]
2. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
Brown MA; Davis CS; Fleming LW; Fleming JW
J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
[TBL] [Abstract][Full Text] [Related]
3. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
Strong J; Kruger D; Novak L
Curr Med Res Opin; 2017 Apr; 33(4):785-793. PubMed ID: 28132529
[TBL] [Abstract][Full Text] [Related]
6. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Bonadonna RC; Renard E; Cheng A; Fritsche A; Cali A; Melas-Melt L; Umpierrez GE
Diabetes Res Clin Pract; 2018 Aug; 142():19-25. PubMed ID: 29649539
[TBL] [Abstract][Full Text] [Related]
7. [Medication of the month. Insulin glargine (Lantus)].
Scheen AJ
Rev Med Liege; 2004 Feb; 59(2):110-4. PubMed ID: 15112902
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.
Saini NK; Wasik B; Pires J; Leale DM; Quach N; Culp WTN; Samms RJ; Johnson AE; Owens JG; Gilor C
Domest Anim Endocrinol; 2021 Apr; 75():106595. PubMed ID: 33307335
[TBL] [Abstract][Full Text] [Related]
9. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN; Syed YY
BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
[TBL] [Abstract][Full Text] [Related]
10. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
12. [Humalog® 200 U/ml KwikPen™].
Scheen AJ
Rev Med Liege; 2015 Oct; 70(10):527-31. PubMed ID: 26727843
[TBL] [Abstract][Full Text] [Related]
13. Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
Kovatchev B; Meng Z; Cali AMG; Perfetti R; Breton MD
Diabetes Ther; 2020 Jun; 11(6):1293-1302. PubMed ID: 32304086
[TBL] [Abstract][Full Text] [Related]
14. Basal insulin regime change from Lantus to Toujeo resulted in fewer hypoglycaemic episodes in a 28-year-old man with diabetes mellitus.
Shields A; Sankaranarayanan S
BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27307429
[TBL] [Abstract][Full Text] [Related]
15. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
16. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
17. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
18. Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
.
Lindauer K; Becker R
Int J Clin Pharmacol Ther; 2019 Jan; 57(1):1-10. PubMed ID: 30369394
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine (Lantus).
Owens DR; Griffiths S
Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
[TBL] [Abstract][Full Text] [Related]
20. The quaternary structure of insulin glargine and glulisine under formulation conditions.
Nagel N; Graewert MA; Gao M; Heyse W; Jeffries CM; Svergun D; Berchtold H
Biophys Chem; 2019 Oct; 253():106226. PubMed ID: 31376619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
